Pfizer’s EU Vyndaqel okay ‘sets up $1.5bn sales next year’Pfizer’s Vyndaqel has become the first drug to be approved for transthyretin amyloidosis with cardiomyopathy (ATTR-CM) in Europe, Share XPfizer’s EU Vyndaqel okay ‘sets up $1.5bn sales next year’https://pharmaphorum.com/news/pfizers-eu-vyndaqel-okay-sets-up-1-5bn-sales-next-year/
